Association between human fetuin-A and the metabolic syndrome: Data from the heart and soul study

Circulation

Volumn 113, Issue 14, 2006, Pages 1760-1767

  Ix, Joachim H ^a,b   Shlipak, Michael G ^b,c   Brandenburg, Vincent M ^d   Ali, Sadia ^c   Ketteler, Markus ^d   Whooley, Mary A ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Alpha2HS glycoprotein; Hypercholesterolemia; Insulin; Lipids; Metabolism

Indexed keywords

BIOLOGICAL MARKER; FETUIN; FETUIN A; HIGH DENSITY LIPOPROTEIN; INSULIN; LIVER PROTEIN; LOW DENSITY LIPOPROTEIN; SECRETORY PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ALPHA2HS GLYCOPROTEIN; PLASMA PROTEIN;

ADULT; AGED; ARTICLE; ATHEROGENESIS; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; HYPERTENSION; INFLAMMATION; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OUTPATIENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; CLINICAL TRIAL; CONFIDENCE INTERVAL; HEART INFARCTION; METABOLISM; METHODOLOGY; MULTICENTER STUDY; PHOTOMETRY; UNITED STATES;

AGED; BLOOD PROTEINS; CONFIDENCE INTERVALS; CORONARY DISEASE; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MYOCARDIAL INFARCTION; NEPHELOMETRY AND TURBIDIMETRY; SAN FRANCISCO;

EID: 33646690516     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.588723     Document Type: Article

References (38)

1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
2. Klein BE, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in beaver dam. Diabetes Care. 2002;25:1790-1794.
3. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716.
4. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
5. Deedwania PC. Metabolic syndrome and vascular disease: is nature or nurture leading the new epidemic of cardiovascular disease? Circulation. 2004;109:2-4.
6. Reaven GM. Banting Lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
7. Auberger P, Falquerho L, Contreres JO, Pages G, Le Cam G, Rossi B, Le Cam A. Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell. 1989;58:631-640.
8. Haasemann M, Nawratil P, Muller-Esterl W. Rat tyrosine kinase inhibitor shows sequence similarity to human alpha 2-HS glycoprotein and bovine fetuin. Biochem J. 1991;274(pt 3):899-902.
9. Kalabay L, Chavin K, Lebreton JP, Robinson KA, Buse MG, Arnaud P. Human recombinant alpha 2-HS glycoprotein is produced in insect cells as a full length inhibitor of the insulin receptor tyrosine kinase. Horm Metab Res. 1998;30:1-6.
10. Mathews ST, Singh GP, Ranalletta M, Cintron VJ, Qiang X, Goustin AS, Jen KL, Charron MJ, Jahnen-Dechent W, Grunberger G. Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes. 2002;51:2450-2458.
11. Rauth G, Poschke O, Fink E, Eulitz M, Tippmer S, Kellerer M, Haring HU, Nawratil P, Haasemann M, Jahnen-Dechent W, Muller-Esterl W. The nucleotide and partial amino acid sequences of rat fetuin: identity with the natural tyrosine kinase inhibitor of the rat insulin receptor. Eur J Biochem. 1992;204:523-529.
12. Srinivas PR, Goustin AS, Grunberger G. Baculoviral expression of a natural inhibitor of the human insulin receptor tyrosine kinase. Biochem Biophys Res Commun. 1995;208:879-885.
13. Srinivas PR, Wagner AS, Reddy LV, Deutsch DD, Leon MA, Goustin AS, Grunberger G. Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol. 1993;7:1445-1455.
14. Vionnet N, Hani El H, Dupont S, Gallina S, Francke S, Dotte S, De Matos F, Durand E, Lepretre F, Lecoeur C, Gallina P, Zekiri L, Dina C, Froguel P. Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet. 2000;67:1470-1480.
15. Kissebah AH, Sonnenberg GE, Myklebust J, Goldstein M, Broman K, James RG, Marks JA, Krakower GR, Jacob HJ, Weber J, Martin L, Blangero J, Comuzzie AG. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci U S A. 2000;97:14478-14483.
16. Cintron VJ, Ko MS, Chi KD, Gross JP, Srinivas PR, Goustin AS, Grunberger G. Genetic mapping and functional studies of a natural inhibitor of the insulin receptor tyrosine kinase: the mouse ortholog of human alpha2-HS glycoprotein. Int J Exp Diabetes Res. 2001;1:249-263.
17. Grunberger GMS, Deutsch DD. Tyrosine kinase inhibitors. In: Insulin Signaling: From Cultured Cells to Animal Models: Frontiers in Animal Diabetes Research. New York, NY: Taylor and Francis; 2002.
18. Mathews ST, Srinivas PR, Leon MA, Grunberger G. Bovine fetuin is an inhibitor of insulin receptor tyrosine kinase. Life Sci. 1997;61:1583-1592.
19. Beattie MS, Shlipak MG, Liu H, Browner WS, Schiller NB, Whooley MA. C-reactive protein and ischemia in users and nonusers of beta-blockers and statins: data from the Heart and Soul Study. Circulation. 2003;107:245-250.
20. Ix JH, Shlipak MG, Liu HH, Schiller NB, Whooley MA. Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: the Heart and Soul Study. J Am Soc Nephrol. 2003;14:3233-3238.
21. Ruo B, Rumsfeld JS, Hlatky MA, Liu H, Browner WS, Whooley MA. Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA. 2003;290:215-221.
22. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003;361:827-833.
23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
24. Clauss A. Rapid physiological coagulation method in determination of fibrinogen [in German]. Acta Haematol. 1957;17:237-246.
25. Cockroft DL. Comparison of in vitro and in vivo development of rat foetuses. Dev Biol. 1976;48:163-172.
26. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294:326-333.
27. Jensen MD, Caruso M, Heiling V, Miles JM. Insulin regulation of lipolysis in nondiabetic and IDDM subjects. Diabetes. 1989;38:1595-1601.
28. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest. 1995;95:158-166.
29. Brinton EA, Eisenberg S, Breslow JL. Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein- cholesterol levels with or without hypertriglyceridemia. J Clin Invest. 1991;87:536-544.
30. Jahnen-Dechent W, Schinke T, Trindl A, Muller-Esterl W, Sablitzky F, Kaiser S, Blessing M. Cloning and targeted deletion of the mouse fetuin gene. J Biol Chem. 1997;272:31496-31503.
31. Price PA, Thomas GR, Pardini AW, Figueira WF, Caputo JM, Williamson MK. Discovery of a high molecular weight complex of calcium, phosphate, fetuin, and matrix gamma-carboxyglutamic acid protein in the serum of etidronate-treated rats. J Biol Chem. 2002;277:3926-3934.
32. Schinke T, Amendt C, Trindl A, Poschke O, Muller-Esterl W, Jahnen-Dechent W. The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells: a possible role in mineralization and calcium homeostasis. J Biol Chem. 1996;271:20789-20796.
33. Beckman JA, Ganz J, Creager MA, Ganz P, Kinlay S. Relationship of clinical presentation and calcification of culprit coronary artery stenoses. Arterioscler Thromb Vasc Biol. 2001;21:1618-1622.
34. Huang H, Virmani R, Younis H, Burke AP, Kamm RD, Lee RT. The impact of calcification on the biomechanical stability of atherosclerotic plaques. Circulation. 2001;103:1051-1056.
35. Cheng GC, Loree HM, Kamm RD, Fishbein MC, Lee RT. Distribution of circumferential stress in ruptured and stable atherosclerotic lesions: a structural analysis with histopathological correlation. Circulation. 1993;87:1179-1187.
36. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103:1813-1818.
37. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation. 2003;107:391-397.
38. Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest. 1979;64:1118-1129.